Tag Archives: Axim

Axim Biotechnologies Inc (OTCMKTS:AXIM) is picking up some strength on the back of a recent SeeThruEquity research report, and a related price target of $17 a share. At last close, the company traded for $10.75 a piece – a more than 37% run...

Medical Marijuana Inc (OTCMKTS:MJNA) just announced that Axim Biotechnologies Inc (OTCMKTS:AXIM) has entered into a term sheet that will see it develop a Marinol bioequivalent. For those not familiar with the relationship between these two...

Axim Biotechnologies Inc (OTCMKTS:AXIM) is one of the few cannabis plays that picked up some strength on the back of the recreational cannabis ballots at the end of last year, and has since managed to build on the traction and continue to gain...

Axim Biotechnologies Inc (OTCMKTS:AXIM) just announced that it has completed enrollment in its lead irritable bowel syndrome (IBS) trial, and the company has picked up a couple of percentage points on the news. Axim is still down close to 60%...

During the second week of January, we published this piece, highlighting the data that Axim Biotechnologies Inc (OTCMKTS:AXIM) management took to the stage at the JP Morgan healthcare conference to present. As noted at the time, the data wasn’t...

Here at Insider Financial, we’ve covered Axim Biotechnologies Inc (OTCMKTS:AXIM) on a number of occasions, be it directly or by way of a Medical Marijuana Inc (OTCMKTS:MJNA) focus. The latter holds a major portion of the former, and so...

Axim Biotechnologies Inc (OTCMKTS:AXIM) is running up up on news of its development pipeline advancing in some key early stage studies, and the company is drawing plenty of speculative capital as a result. There’s a lot of capital flowing...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter